Reports Q2 revenue $67.491M, consensus $51.02M. Commenting on the Company, Aaron Berg, Amarin’s President and CEO, said, “As I begin in my new role as CEO of Amarin, my focus is clear: drive value by focusing on operational execution and performance while urgently evaluating opportunities to expand the impact of VASCEPA/VAZKEPA to benefit millions of patients worldwide. That is our commitment to patients, providers, employees and of course, shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRN:
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
- Amarin Announces New CEO Aaron Berg and Incentive Plan
- AMRN Earnings this Week: How Will it Perform?
- Amarin gets reimbursement approval for Vazkepa in Portugal
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
Questions or Comments about the article? Write to editor@tipranks.com